Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
AssigneeNeuroDerm, Ltd.
InventorsOron Yacoby-Zeevi, Mara Nemas
Life of this patent
Estimating the term…
Abstract
Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Claims23
A pharmaceutically acceptable liquid composition comprising:
- (a) active components comprising:
- (i) about 5% to about 20% by weight levodopa;
- and
- (ii) carbidopa;
- and
- (b) about 20% to about 40% by weight arginine, meglumine, or a combination thereof;
- wherein said composition is at a pH of about 9.1 to about 9.8 at 25° C.
A pharmaceutically acceptable liquid composition comprising:
- (a) about 10% to about 20% by weight levodopa;
- (b) about 1% to about 6% by weight carbidopa;
- and
- (c) about 20% to about 40% by weight arginine and/or meglumine, wherein said composition has a pH of about 9.1 to about 9.8 at 25° C.
A pharmaceutically acceptable liquid composition comprising:
- (a) about 12% by weight levodopa;
- (b) about 1% to about 4% by weight carbidopa;
- (c) arginine and/or meglumine in a molar ratio of levodopa and carbidopa to arginine or meglumine of about 1:1.8 to about 1:3.5;
- (d) about 0.2% to about 2% by weight sodium ascorbate;
- and
- (e) L-cysteine or NAC
- wherein said composition is at a pH of about 9.1 to about 9.8 at 25° C.
Dependencies are inferred from the claim text.